Advanced search
Show most relevant results first | Most recent results are first | Show use by person

Results 1-5 of 5 for in 'Dáil debates' segment:8918185

Saincheisteanna Tráthúla - Topical Issue Debate: Medicinal Products (9 May 2024)

Violet-Anne Wynne: I thank the Minister of State for the new statistics showing that 362 licences have been issued, which is very positive. Recently a patient reached out to me who had applied for a ministerial licence. The Minister for Health will be very familiar with this case because I submitted a number of parliamentary questions on the matter. What has come to light is that because the consultant is...

Saincheisteanna Tráthúla - Topical Issue Debate: Medicinal Products (9 May 2024)

Mary Butler: As I stated earlier, the Department is currently establishing a clinical review group to review the publication to make recommendations to the Minister for Health. In response to an oral parliamentary question last week, he stated that he would be open to any expansion, if recommended, but that he would be entirely led by the clinicians in the group. The Deputy spoke about a specific...

Saincheisteanna Tráthúla - Topical Issue Debate: Medicinal Products (9 May 2024)

Medicinal Products

Saincheisteanna Tráthúla - Topical Issue Debate: Medicinal Products (9 May 2024)

Violet-Anne Wynne: I am delighted that this Topical Issue was selected and thank the Office of the Ceann Comhairle for facilitating this important discussion. It is an issue I am very passionate about and I hope to shed a bit of light on what the medical cannabis access programme, MCAP, and the ministerial licence mean. As we all know, the MCAP was established in 2019 as a five-year pilot scheme. However,...

Saincheisteanna Tráthúla - Topical Issue Debate: Medicinal Products (9 May 2024)

Mary Butler: I thank the Deputy for her question. She raised two distinct issues, which I shall address in order. The MCAP is operated by the primary care reimbursement service of the HSE and is a statutory programme to enable clinicians and patients to access prescribed cannabis-based products for the treatment of three conditions as specified in the HPRA 2017 report Cannabis for Medical Use-A...

   Advanced search
Show most relevant results first | Most recent results are first | Show use by person